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Abstract 
Background: Stromal vascular fraction (SVF) can easily be obtained from a mini-lipoaspirate procedure of fat tissue 
and platelet rich plasma (PRP) can be obtained from peripheral blood. The SVF contains a mixture of cells including 
ADSCs and growth factors and has been depleted of the adipocyte (fat cell) population. We evaluated the safety and 
efficacy of administering SVF and PRP intra-discally into patients with degenerative disc disease.
Methods: A total of 15 patients underwent a local tumescent liposuction procedure to remove approximately 60 ml 
of fat tissue. The fat was separated to isolate the SVF and the cells were delivered into the disc nucleus of patients with 
degenerative disc disease. The subjects were then monitored for adverse events, range of motion, visual analog scale 
(VAS), present pain intensity (PPI), Oswestry Disability Index (ODI), Beck Depression Inventory (BDI), Dallas Pain Ques-
tionnaire and Short Form (SF)-12 scores over a period of 6 months. Safety events were followed for 12 months.
Results: No severe adverse events (SAEs) were reported during a 12 month follow up period with no incidences of 
infection. Patients demonstrated statistically significant improvements in several parameters including flexion, pain 
ratings, VAS, PPI, and short form questionnaires. In addition, both ODI and BDI data was trending positive and a major-
ity of patients reported improvements in their Dallas Pain Questionnaire scores.
Conclusions: Overall, patients were pleased with the treatment results. More importantly, the procedure demon-
strated a strong safety profile with no severe adverse events or complications linked to the therapy.
Trial registration NCT02097862. Name of registry: www.clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT020978
62?term=bioheart&rank=6. Date of registration: March 25, 2014; Date of enrollment: March 2014
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Background
Degenerative disc disease (DDD) is a condition associ-
ated with the degeneration of one or more of the discs 
in the spine. DDD can cause severe chronic pain in the 
low back which can radiate to the hips and legs. There 
can be severe inflammation and degeneration of the 
fibrocartilage.
Recent studies have focused on the use of adult stem 
cells for disorders such as degenerative disc disease. Mes-
enchymal stem cells (MSCs) are non-hematopoietic, 
multipotent progenitor cells, which can be isolated from 
various human adult tissues. The potential to form cells 
of multi-lineages has indicated the potential of these 
cells in cases of degenerative disc disease. In recent 
years, MSCs have been shown to possess broad range of 
regenerative capabilities, modulating disease progression 
repairing lesions so closely associated with degenera-
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regenerative biologic agent because of their ability to dif-
ferentiate into multiple tissue types and to self-renew.
The paracrine activity of MSCs is thought to be one 
of the major means by which these cells mediate anti-
inflammatory, anti-apoptotic, anti-fibrotic, angiogenic, 
mitogenic and wound healing properties. The complex 
interplay of the biological mediators secreted by MSCs 
has been shown to be important in regulating regen-
eration of damaged or diseased organs and tissues of the 
body. It has also been shown that the pre-curser to the 
MSC is the pericyte which are the cells present on the 
microvessels and capillaries throughout the body. These 
cells become “activated” when an injury is recognized and 
detach to become medicinal MSCs. An immune-modula-
tory effect is initiated where other cells are called to help 
with the healing process while other secreted molecules 
will establish a regenerative microenvironment by setting 
up a trophic field [3].
Recent studies have identified adipose tissue as a new 
source of mesenchymal stem cells. As lipoaspiration pro-
vides relatively simple access to this stem cell pool, and 
with the large numbers of cells present in adipose tissue, 
its future potential as a stem cell reservoir for degenera-
tive disc disease is promising.
Stem cells derived from a patient’s own fat are referred 
to as adipose-derived stem cells [4]. Adipose-derived 
stem cells or ADSCs are multi-potential in that they 
have the ability to differentiate into a variety of different 
types of tissue including but not limited to bone, carti-
lage, muscle, and fat. These cells have also been shown to 
express a variety of different growth factors and signaling 
molecules (cytokines), which recruit other stem cells to 
facilitate repair and healing of the affected tissue. ADSCs 
are very angiogenic in nature and can promote the 
growth of new blood vessels. In addition, ADSCs might 
play a role in the local inflammatory process [5, 6].
A stromal vascular fraction (SVF) can easily be isolated 
from fat tissue in approximately 30–90  min in a clinic 
setting using a mini-lipoaspirate technique. The SVF 
contains a mixture of cells including ADSCs and growth 
factors and has been depleted of the adipocyte (fat cell) 
population. It has been shown that cells isolated from 
the SVF contain an abundance of CD34+ cells [7]. This 
marker is present on both pericytes and mesenchymal 
cells. Cells expressing CD34 are also known to reside in 
a periendothelial location and stabilize endothelial net-
works. SVF can be used in a point of care setting for a 
variety of indications and is currently being used in thou-
sands of clinics world-wide with varying degrees of suc-
cess reported. Adipose tissue is quickly becoming the 
preferred source for point of care treatments in clinic due 
to the high number of MSCs that can be obtained and the 
low number of leukocytes as compared to bone marrow 
[8]. In addition, adipose tissue has a significantly higher 
amount of pericytes which are the precursors to MSCs 
[9, 10].
Stem cells from adipose tissue offer a novel therapy 
for patients with degenerative disc disease. SVF injected 
directly into the disc may reduce inflammation and pro-
mote healing. SVF is an attractive therapeutic method 
given that the harvesting process is safe and the cells are 
readily available in usually large quantities. In Vitro stud-
ies have demonstrated that ADSCs are able to stimulate 
matrix synthesis and cell proliferation of degenerated 
nucleus pulpous cells. This may promote the restoration 
of damaged nucleus cells in a degenerated disc [11]. In a 
murine model of chronic disc degeneration, ADSC trans-
plantation promoted new expression of proteoglycans 
and increased levels of aggrecan [12]. ADSCs were also 
studied in a rabbit model of degenerative disc disease. 
The ADSC injected discs exhibited elevated extracellular 
matrix and minimal ossification as compared to the con-
trol discs [13].
Platelet rich plasma is a mixture of growth factors and 
fibrin obtained from autologous peripheral blood. PRP 
has been utilized in a variety of musculoskeletal indi-
cations with evidence of anti-inflammatory and heal-
ing properties. One study demonstrated that intradiscal 
injections of PRP led to symptomatic clinical benefit in 
individuals with chronic discogenic lower back pain [14]. 
By combining PRP with SVF, there may be an increased 
number of growth factors anad proteins which could 
translate to improved patient outcomes.
Pettine, et al. have reported on the use of bone marrow 
concentrate to treat discogenic pain as an alternative to 
surgery. The cells were injected directly into the nucleus 
pulposus with no complications reported. There was a 
71% reduction in VAS pain scales and ODI improvements 
through 2 years [15]. In another pilot study, patients with 
degenerative disc disease were injected into the nucleus 
pulpous area with culture expanded autologous bone 
marrow MSCs. Patients exhibited rapid improvement of 
pain and disability and elevated water content in the disc 
at the 12 month follow up [16]. We report the safety and 
preliminary efficacy results of intradiscal SVF and PRP 
administration in patients with degenerative disc disease.
Methods
Study design
The open label study was conducted on 15 patients with 
degenerative disc disease. The protocol was approved by 
the institutional review board and all patients provided 
written informed consent. SVF was injected directly 
into the nucleus pulpous under fluoroscopic guidance. 
Clinical evaluations were scheduled at baseline, 2, and 
6  months. The primary safety endpoint was serious 
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adverse events (SAEs) and were defined as any event that 
was fatal or life-threatening, led to hospitalizations, or 
required major medical intervention. Physical param-
eters including height, weight, blood pressure, pulse and 
low back range of motion as measured by inclinometer 
were collected. Patients were evaluated for visual analog 
score (VAS), present pain index (PPI), and minimum, 
maximum, and current pain ratings. Psychological data 
was also collected including Beck Depression Inven-
tory (BDI), Oswestry Disability Index (ODI), Short Form 
McGill Pain Questionnaire (SM-MPQ), Short Form 12 
(SF-12), and the Dallas Pain Questionnaire.
Patient eligibility
Patients age 18–90  years with degenerative disease 
of one, two or three lumbar discs with predominant 
back pain after conservative treatment (physical and 
medical) for over 6  months were eligible for the study. 
Patients must have a fibrous ring capable of holding 
the cell implantation as demonstrated by MRI image. 
Patients with congenital or acquired diseases leading to 
spinal deformations, active cancer or infections includ-
ing human immunodeficiency virus, hepatitis B or C, 
or cytomegalovirus were excluded. In addition, patients 
with spinal segmental instability, spinal canal steno-
sis, isthmus pathology, more than 50% loss of height, or 
modic III changes on MRI images were also excluded 
from the study.
Cell preparation and study intervention
From each patient, approximately 60 ml fat was collected 
using a 3  mm aspiration cannula with prior adminis-
tration of tumescent solution. The tissue was prepared 
using an adipose stromal vascular fraction preparation 
kit (US Stem Cell, Inc. Sunrise, FL). The adipose tis-
sue was washed with buffered saline and digested using 
collagenase (Cellase, US Stem Cell, Inc., Sunrise, FL) at 
37 °C for 12–15 min with agitation at 5-minute intervals. 
The suspension was centrifuged at 1200×g for 5 min to 
collect the SVF as a pellet. The pellet was washed twice 
and filtered through a 100 μm cell strainer with buffered 
saline to remove any residual enzyme. The final SVF pel-
let was resuspended in approximately 1–3  ccs of autol-
ogous platelet rich plasma (PRP). PRP was prepared by 
collecting autologous peripheral blood and centrifuging 
at 500 g for 8 min.
Patients placed in a prone position on the fluoroscopy 
table. Standard sterile preparation and local anesthesia 
was administered. Anteroposterior and lateral fluoro-
scopic imaging was utilized to confirm proper needle 
position in the nuclei of the disc. A small amount of 
contrast agent was injected followed by approximately 
1 cc of SVF/PRP suspension. If more than one disc was 
symptomatic, the SVF was divided and prepared with 
approximately 1 cc of PRP.
Outcomes
The primary safety outcome was the incidence of SAEs 
over 6  months. The efficacy outcomes included visual 
analog score (VAS), present pain index (PPI), and mini-
mum, maximum, and current pain ratings. Psychological 
data was also collected including Beck Depression Inven-
tory (BDI), Oswestry Disability Index (ODI), Short Form 
McGill Pain Questionnaire (SM-MPQ), Short Form 12 
(SF-12), and the Dallas Pain Questionnaire. This study 
was designed to primarily assess the safety and feasibil-
ity of the intradiscal SVF transplantation procedure and 
secondarily to provide preliminary data regarding the 
efficacy of intradiscal SVF transplantation. Formal power 
calculations were not performed. Paired T test statisti-
cal analyses were performed and confidence intervals are 
presented with 95% degree of confidence. All statistical 
tests used a significance level of α ≤ 0.05.
Results
Patient baseline evaluation
A total of 15 patients were enrolled in the study and 
treated at one clinical site. Seventy-three percent of the 
patients were male and 27% female with an average age of 
51.5 (range 32–76). A total of 15 patients completed fol-
low up at 2 and 6 months.
Adipose and SVF collection
All procedures were well tolerated and uneventful, 
resulting in a collection of approximately 60  ccs of adi-
pose tissue. Approximately 30–60 million SVF cells were 
obtained. According to validation studies, the population 
obtained is at least 50% positive for CD34 with a viability 
of greater than 90% (data not shown). In addition to test-
ing the proliferation capacity of the cells, differentiation 
assays for adipogenesis (fat), osteogenesis (Bone) and 
chondrogenesis (cartilage) were completed. The samples 
shown in Fig. 1 displayed positive differentiation results 
confirming the presence of multi-potential mesenchymal 
stem cells.
Transplantation procedure
The transplantation procedure was successful in 15/15 
patients. Patients received approximately 30–60 million 
cells in 1–3  ccs volume of PRP. A volume of approxi-
mately 1 cc of cells in PRP were placed directly into the 
nuclei of each disc as determined by fluoroscopy.
Efficacy outcomes
Patients demonstrated improvements in flexion over the 
6  month follow up period (Fig.  2). Figure  2a shows the 
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average flexion at baseline, 2 and 6 months post injection. 
Patients demonstrated positive trends with an increase in 
pelvic, lumbar and total flexion over the 6 months period. 
Figure 2b shows the average change in flexion over base-
line at both 2 and 6 months. All data points were trend-
ing in the positive direction with a statistically significant 
(p = 0.02) improvement in total flexion at 6 months.
Figure 3 shows the pain ratings over the 6 month fol-
low up period. Figure  3a is the Average Pain ratings at 
baseline, 2 and 6 months post injection. Patients experi-
enced a reduction in pain from baseline to 2 months and 
again from 2 to 6 months. Figure 3b displays the average 
change in pain ratings at 2 and 6 months over baseline. 
The majority of patients (10) were reporting less pain at 
6  months post injection as compared to baseline. Both 
the minimum and current pain ratings scores showed 
statistically significant improvements (p  =  0.05 and 
p = 0.01 respectively).
Patients reported a reduction in pain and discomfort 
according to both VAS and PPI (Fig. 4). VAS scores statis-
tically improved from an average of 5.6 at baseline to 3.6 
at 6 months (p = 0.01). PPI scores statistically improved 
from an average of 2.6 at baseline to 1.8 at 6  months 
(p = 0.03). Figure 4b shows the average improvement in 
outcome scores for VAS and PPI.
Psychological data ODI and BDI results displayed a 
modest improvement (Fig. 5a, b). The data did not reach 
statistical significance at either 2  months or 6  months 
(Fig. 5c).
The Dallas Pain Questionnaire results are shown in 
Fig. 6. There are 16 questions which are divided into four 
Fig. 1 a Adipogenesis fat differentiation (Oil Red-O), b osteogenesis 
bone differentiation (Alizarin Red S), c chondrogenic cartilage dif-
ferentiation (toluidine blue sodium borate stain)
Fig. 2 a Average flexion, b average change in flexion
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sections including: D1 daily activities, D2 work/leisure 
activities, D3 anxiety/depression, and D4 social interest. 
Figure 6a shows the values of the four sections at base-
line, 2 and 6 months. On average, patients demonstrated 
a slight improvement in their daily activities and work/
leisure activities at both 2 and 6 months. Patients, how-
ever, demonstrated a slight increase in anxiety/depres-
sion and reduction in social interest. Figure  6b shows 
the percentage of patients that improved in each param-
eter of the questionnaire. A majority of patients showed 
improvements at both 2 and 6  months for daily activi-
ties and work/leisure activities. In addition, a majority 
of patients showed improvements in anxiety and social 
interest at 2 months and 30 and 40% respectively showed 
improvements at 6 months.
Results for both the Short Form McGill Pain Ques-
tionnaire and the Short Form 12 are shown in Fig. 7. The 
SF-MPQ provides valuable information on the sensory, 
affective and evaluative dimensions of pain experience 
with higher numbers indicating more pain and lower num-
bers indicating less pain. The SF12 is a generic measure 
that can provide glimpses into mental and physical func-
tioning and overall health-related-quality of life to provide 
easily interpretable scales for physical and mental health. 
Physical and mental health composite scores (PCS & 
MCS) are computed using the scores of twelve questions, 
where a zero score indicates the lowest level of health and 
100 indicates the highest level of health. Figure 7a shows 
the average short form questionnaire values and 7b shows 
the average change/improvement from baseline. Patients 
reported a slight improvement in SF-MPQ and a statis-
tically significant improvement at 6  months (p  =  0.05). 
Patients also reported a significant improvement in SF12-
PCS at 6  months (p  =  0.03). No significant changes in 
SF12 at either time point were observed.
Safety analysis
No severe adverse events (SAEs) were reported dur-
ing a 12 month follow up period. Other reported events 
included soreness in the abdomen after the mini-liposuc-
tion procedure or soreness in the back after injections. 
Patients were instructed to take previously prescribed 
opioids for pain and all events resolved within 7–10 days. 
All occurrences resolved without intervention. There 
were no incidences of infection.
Fig. 3 a Average pain ratings, b average change in pain ratings Fig. 4 a Average visual analog score and present pain index, b Aver-
age change in VAS and PPI
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Discussion
Degenerative disc disease is associated with symptoms 
of pain and possibly radiating weakness or numbness 
with limited clinical options. Until recently, patients 
had few options. Surgery requires extensive recovery, 
and time away from work, usually at least 6 weeks. Also, 
the risk of complications is significant. Aside from the 
complications that might arise from anesthesia, there is 
a 1 in 10,000 risk of bowel or bladder incontinence and 
a 1 in 1000 risk of nerve root damage. There may also be 
1–3% risk of CSF leak, 1% infection risk and 5–10% risk 
of spinal instability [17].
In recent years, stem cell therapy has developed with 
promising preclinical results and preliminary clinical 
results. Adipose derived stem cells as part of the stromal 
vascular fraction are a feasible candidate for degenera-
tive indications. The SVF does not require in  vitro cul-
ture expansion and is easy to collect bedside. These cells 
can be placed directly into the nuclei of the disc utiliz-
ing a minimally invasive injection technique guided by 
fluoroscopy.
This clinical study demonstrated the safety and feasibil-
ity of utilizing the SVF in degenerative disc patients. No 
major safety issues were noted and the procedures were 
well tolerated in all patients. In addition, patients dem-
onstrated statistically significant improvements in sev-
eral parameters including flexion, pain ratings, VAS, PPI, 
and short form questionnaires. Although ODI and BDI 
did not show statistically significant changes due to the 
low number of subjects in the trial, the data was trend-
ing positive. In addition, a majority of patients reported 
improvements in their Dallas Pain Questionnaire scores.
Fig. 5 a Average oswestry disability index, b average beck depres-
sion inventory, c average change in ODI and BDI
Fig. 6 a Average dallas pain questionnaire results, b percentage of 
patients with improvements in dallas pain questionnaire
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Although this study suggests that the use of SVF is safe 
and feasible, the general under powering of the study 
coupled with the lack of placebo control would render 
additional studies necessary to determine the true clini-
cal effect of the treatment. In addition, several patients 
were lost to follow up which could compound the data 
and create patient bias. Given the encouraging results on 
this small sample size with statistical significance, large 
appropriately powered clinical studies blinded to both 
clinical staff and patients are warranted.
Conclusion
The current study sought to define the safety and feasi-
bility of intradiscal transplantation of autologous SVF in 
patients with degenerative disc disease. Several param-
eters demonstrated statistically significant improvements 
over a 6 month time period. A true evaluation of efficacy 
and safety would require larger phase II/III studies. How-
ever, the current study does provide encouraging feasi-
bility data regarding the intradiscal stem cell treatment 
and suggests some clinical benefit of the SVF therapy in 
degenerative disc patients.
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